Drug class
Spleen tyrosine kinase (SYK) inhibitor; immunomodulatory small molecule
Mechanism of action
Fostamatinib is converted to the active metabolite R406, which inhibits SYK signalling downstream of Fc receptors in macrophages and other immune cells. This reduces antibody-mediated platelet phagocytosis in immune thrombocytopenia.
General use cases
- Treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
